Ovarian Cancer Update
About LCU CME Meetings Patterns of Care Patient Projects
You are here: Home: Audio Program Guide: OCU 1 | 2008 Audio: OCU 1 | 2008
 
 
  Go to interview with Robert F Ozols, MD, PhD
Go to interview with Maurie Markman, MD
Go to interview with Thomas J Herzog, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Ozols, MD Robert F Ozols, MD, PhD
Senior Vice President, Medical Science
Fox Chase Cancer Center
Philadelphia, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Overview of staging at diagnosis and treatment of ovarian cancer
Track 2 Treatment and prognosis of recurrent ovarian cancer
Track 3 Adjuvant clinical trials evaluating new treatment regimens compared to carboplatin/paclitaxel
Track 4 Single-agent bevacizumab in previously treated patients with recurrent ovarian cancer
Track 5 GOG-0218: Carboplatin/paclitaxel versus carboplatin/paclitaxel/bevacizumab with or without extended bevacizumab in Stage III or IV ovarian epithelial or primary peritoneal cancer
Track 6 Bevacizumab-associated gastrointestinal perforations in advanced ovarian cancer

Track 7 Clinical use of bevacizumab in advanced ovarian cancer
Track 8 Biologic agents being evaluated for the treatment of ovarian cancer
Track 9 Phase II trial of gemcitabine with or without pertuzumab for platinum-resistant ovarian cancer
Track 10 Eligibility criteria for GOG-0218
Track 11 Identifying predictors of response to pertuzumab
Track 12 Challenges in completing clinical trials in ovarian cancer
Track 13 Continuation of bevacizumab after disease progression
Track 14 Mechanism of action of bevacizumab in ovarian cancer
Track 15 Treatment of platinum-resistant disease
Track 16 Prevention and treatment options for women with BRCA1/2 mutations
Track 17 Mechanism(s) of action of PARP inhibitors
Track 18 Primary peritoneal carcinomatosis
Track 19 Evaluation of biomarkers for early detection of ovarian cancer
Track 20 Staging laparotomy in ovarian cancer
     
Markman, MD Maurie Markman, MD
Vice President for Clinical Research
The University of Texas MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Historical perspective on the treatment of ovarian cancer
Track 2 Stage of ovarian cancer at presentation in the US
Track 3 Prognosis and treatment of patients with advanced suboptimally or optimally resected ovarian cancer
Track 4 Sites of metastases in advanced ovarian cancer
Track 5 Optimal surgical cytoreduction in advanced ovarian cancer
Track 6 Neoadjuvant chemotherapy as an alternative to aggressive up-front surgery
Track 7 Molecular markers and targeted therapies in ovarian cancer

Track 8 Clinical trials evaluating pertuzumab
Track 9 EGFR overexpression in ovarian cancer
Track 10 Response to bevacizumab in platinum-resistant, advanced ovarian cancer
Track 11 Potential mechanism(s) of action of bevacizumab in ovarian cancer
Track 12 Duration of bevacizumab in GOG-0218
Track 13 Side effects and toxicity of bevacizumab
Track 14 Use of single-agent bevacizumab in advanced ovarian cancer
audio
Track 15 Treatment of ovarian cancer by gynecologic versus medical oncologists
Track 16 Intraperitoneal chemotherapy for patients with residual disease after surgery
Track 17 Treatment options after progression on first-line therapy for advanced ovarian cancer
audio
     
Herzog, MD Thomas J Herzog, MD
Physicians and Surgeons Alumni Professor of Clinical Obstetrics and Gynecology
Director, Division of Gynecologic Oncology
National Cancer Institute Designated Comprehensive Cancer Center
Columbia University Medical Center
New York, New York
  
  Click here to download the entire interview  
Track 1 GOG-111: Improved outcomes with cisplatin/paclitaxel compared to cisplatin/cyclophosphamide in suboptimal Stage III/IV ovarian cancer
Track 2 GOG-158: Cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal Stage III epithelial ovarian cancer
Track 3 Involvement of medical oncologists in treating advanced ovarian cancer
Track 4 Patient outcomes after surgery performed by gynecologic oncologists versus OB/GYNs
Track 5 GOG-172: Intravenous versus intraperitoneal chemotherapy for optimal Stage III ovarian and primary peritoneal cancer
Track 6 Use of intravenous versus intraperitoneal chemotherapy by specialty and practice setting

Track 7 Catheter-related complications with intraperitoneal therapy
Track 8 Factors influencing the use of intravenous versus intraperitoneal chemotherapy
Track 9 Proposed GOG-606 trial of (neo)adjuvant intravenous chemotherapy in the elderly
Track 10 Rationale for the development of GOG-0218 incorporating bevacizumab with carboplatin/paclitaxel in Stage III or IV ovarian epithelial or primary peritoneal cancer
Track 11 Incidence and contributing factors of bevacizumab-related bowel perforation
Track 12 Eligibility and randomization in GOG-0218
Track 13 Development of a clinical trial to evaluate intraperitoneal chemotherapy and bevacizumab
Track 14 Time interval between administration of bevacizumab and surgery
Track 15 GOG-0213: Adjuvant carboplatin/paclitaxel with or without bevacizumab and/or secondary cytoreduction surgery in platinum-sensitive recurrent ovarian epithelial cancer, primary peritoneal cavity cancer or fallopian tube cancer
Track 16 Off-protocol use of bevacizumab for ovarian cancer

Track 17 Novel agents being evaluated in ovarian cancer, including pertuzumab
Track 18 Use of CA125 to monitor treatment and detect disease progression
Track 19 Time course and cause of death in ovarian cancer

Track 20 Chemosensitivity of ovarian cancer